Kacital

Potassium Citrate, the active ingredient in Kacital, is a potassium salt presented as an oral formulation for oral use. It is employed to increase urinary pH and to correct metabolic acidosis in patients who require an alkalinizing agent.

GNH USA supplies Kacital as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Potassium Citrate acts as an alkalinizing agent to modify urinary chemistry and systemic acid‑base balance. - Calcium kidney stones: helps prevent stone formation by raising urinary citrate and pH. - Metabolic acidosis: corrects low blood bicarbonate levels in conditions such as renal tubular acidosis. - Urinary alkalinization: facilitates the dissolution of certain urinary crystals and improves the efficacy of some antimicrobial therapies.

Potassium Citrate may cause adverse reactions that vary in frequency and severity.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal cramping, or mild diarrhea. - Flatulence: increased gas production. - Taste alteration: a mild metallic or salty taste. - Hyperkalemia: elevated serum potassium, especially in renal impairment.

Serious or Rare Side Effects: - Severe hyperkalemia: can lead to cardiac arrhythmias. - Metabolic alkalosis: excessive alkalinization of blood. - Allergic reactions: rash, itching, or swelling of the face and throat.

Before initiating therapy, consider patient‑specific factors and monitor appropriately. - Renal impairment: assess kidney function and adjust dose if needed. - Hyperkalemia risk: avoid in patients with high baseline potassium levels. - Concomitant potassium‑sparing drugs: monitor serum potassium closely. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk. - Storage: Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Potassium Citrate can influence the pharmacokinetics or pharmacodynamics of several medicines.

Major Interactions (Avoid): - Aluminum‑containing antacids: may bind citrate and reduce absorption. - ACE inhibitors or ARBs: can precipitate dangerous hyperkalemia.

Moderate Interactions (Monitor Closely): - Loop diuretics: may increase potassium loss, requiring electrolyte monitoring. - Sodium bicarbonate: additive alkalinizing effect may cause metabolic alkalosis. - Certain antibiotics (e.g., quinolones): urinary pH changes can affect drug activity.